Rein Therapeutics Enters Material Agreement, Discloses Financial Obligations
Ticker: RNTX · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $6.0 million, $1.0 million, $0.95 m, $1.0 m, $0.95 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Rein Therapeutics just signed a big deal and sold some stock, watch this space.
AI Summary
Rein Therapeutics, Inc. announced on October 23, 2025, that it entered into a material definitive agreement. The company also disclosed the creation of a direct financial obligation and unregistered sales of equity securities. This filing follows a name change from Aileron Therapeutics, Inc. on March 29, 2024.
Why It Matters
This 8-K filing indicates significant corporate activity, including new financial commitments and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, suggesting potential financial shifts and strategic moves that carry inherent risks.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- October 23, 2025 (date) — Date of earliest event reported
- March 29, 2024 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement entered into by Rein Therapeutics?
The filing states that Rein Therapeutics, Inc. entered into a material definitive agreement on October 23, 2025, but does not provide specific details about the agreement itself within the provided text.
What type of direct financial obligation was created by Rein Therapeutics?
The filing indicates the creation of a direct financial obligation by Rein Therapeutics, Inc. on October 23, 2025, but the specific details of this obligation are not elaborated in the provided text.
Were there any unregistered sales of equity securities by Rein Therapeutics?
Yes, the filing reports unregistered sales of equity securities by Rein Therapeutics, Inc. on October 23, 2025.
When did Rein Therapeutics, Inc. change its name from Aileron Therapeutics, Inc.?
Rein Therapeutics, Inc. changed its name from Aileron Therapeutics, Inc. on March 29, 2024.
What is Rein Therapeutics, Inc.'s Standard Industrial Classification (SIC) code?
Rein Therapeutics, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 945 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2025-10-24 17:08:06
Key Financial Figures
- $6.0 million — may request pre-paid advances of up to $6.0 million from Yorkville (each, a "Pre-Paid Advan
- $1.0 million — dvances. An initial Pre-Paid Advance of $1.0 million was purchased on the Effective Date by
- $0.95 m — ("First Advance"), for net proceeds of $0.95 million, and on September 8, 2025, and pu
- $1.0 m — Pre-Paid Advance ("Second Advance") of $1.0 million, for which we received net procee
- $0.95 million — , for which we received net proceeds of $0.95 million. As of the date of this report, we have
- $1 — verage price per share of approximately $1.0562, to Yorkville, which were offset a
- $1,007,342 — to Yorkville, which were offset against $1,007,342 of the outstanding principal and accrue
- $1,003,573 — to Yorkville, which were offset against $1,003,573 of the outstanding principal and accrue
Filing Documents
- d13294d8k.htm (8-K) — 29KB
- 0001193125-25-250175.txt ( ) — 145KB
- rntx-20251023.xsd (EX-101.SCH) — 3KB
- rntx-20251023_lab.xml (EX-101.LAB) — 18KB
- rntx-20251023_pre.xml (EX-101.PRE) — 11KB
- d13294d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: October 24, 2025 /s/ Timothy M. Cunningham Timothy M. Cunningham, Chief Financial Officer